Calidi Biotherapeutics Shares Q3 2025 Financial Results
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a groundbreaking biotechnology company, has recently shared its financial outcomes and pivotal developments from the third quarter of 2025. With a mission to enhance targeted therapies that deliver genetic medicines, Calidi is achieving significant progress through its innovative RedTail platform.
Recent Achievements and Data Presentation
At the recent Society of Immunotherapy for Cancer (SITC) annual meeting, Calidi showcased compelling data regarding its CLD-401 compound. This compound is the first lead candidate from the RedTail platform, designed to protect against immune clearance after systemic administration in preclinical models. The results are promising, indicating that the platform can effectively express genetic therapies directly at tumor sites.
Strong Support from Scientific Advisory Board
To further bolster its research and development efforts, Calidi has established a Scientific Advisory Board comprising leaders in the field. This diverse group will play a critical role in advancing CLD-401 and the entire RedTail platform. Members include renowned medical professionals and oncologists, each bringing decades of valuable experience to the table.
Advancements in Virotherapy
The expansion of the RedTail platform continues to pave the way for advances in virotherapy, not just in oncology but also in other areas of medicine. The company is working on integrating additional payloads and developing programmable membrane technologies for enhanced delivery mechanisms.
Financial Highlights of Q3 2025
For the quarter concluded September 30, 2025, Calidi reported a net loss of $5.2 million, slightly up from $5.1 million compared to the same period in 2024. Notably, the inclusion of a non-cash charge related to the deemed dividend on warrants pushed the total net loss attributable to shareholders to $10.8 million.
Investment and Capital Raising Efforts
Calidi raised $6.9 million in gross proceeds from a public offering that attracted both new and existing investors. This successful round of funding contributes significantly to Calidi's financial health and helps extend its operational runway into future initiatives.
Research and Development Spending
The company's research and development expenditures reached $2.4 million for the quarter, showcasing an increase from $2.2 million in the prior year’s quarter. General and administrative expenses also saw a decrease, further optimizing their operational costs.
About Calidi Biotherapeutics
Calidi Biotherapeutics is at the forefront of clinical-stage immuno-oncology solutions. By leveraging an engineered enveloped oncolytic virus from the RedTail platform, Calidi aims to revolutionize the way genetic medicines are delivered to cancerous tissues. Their work primarily targets diseases with high unmet medical needs, including non-small cell lung cancer and ovarian cancer.
As a company committed to innovation, Calidi is consistently exploring new therapeutic avenues and enhancing its technologies, aiming for successful IND-enabling studies that will fortify its clinical approaches.
Frequently Asked Questions
What is the primary focus of Calidi Biotherapeutics?
Calidi Biotherapeutics focuses on developing targeted therapies that can deliver genetic medicines to treat various forms of cancer and other diseases.
What recent data did Calidi present at SITC?
Calidi presented data demonstrating the efficacy of its CLD-401 compound, which protects against immune clearance using their proprietary RedTail platform.
Who comprises Calidi's Scientific Advisory Board?
The Scientific Advisory Board includes esteemed professionals with extensive experience in drug development and oncology research, enhancing Calidi's strategic direction.
How much capital did Calidi raise in its latest funding round?
Calidi raised $6.9 million in gross proceeds from an underwritten public offering aimed at boosting its financial foundation.
What are the financial results for Q3 2025?
Calidi reported a net loss of $5.2 million for Q3 2025, with a significant increase in the loss attributable to shareholders due to non-cash charges.
